Roger Barker

University of Cambridge

Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke's Hospital Cambridge. He is a guest professor at the University of Lund, Sweden and a PI in the MRC-Wellcome Trust Stem Cell Institute in Cambridge. For the last 25 years he has run research that seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson's (PD) and Huntington's disease (HD). This has helped him define the best way by which to take new treatments into the clinic, in particular cell based therapies. He currently co-ordinates an EU funded transplant programme using human fetal tissue for patients with PD and is part of a new EU and global initiative (GFORCE-PD) that is seeking to take stem cells to trial in patients with PD.

Presentation(s):

• (Stem) Cell based therapis for Parkinson's disease- Where are we?

  6/19/2018
  15:10 – 15:40

• Overview of the ISSCR's Clinical Translation Committee's work

  6/20/2018
  11:05 – 11:25

• 1 - TOPIC OVERVIEW BY CHAIR

  6/21/2018
  16:00 – 16:05

• 6 - LESSONS LEARNED FROM A CELL-BASED TRIAL IN PARKINSON’S DISEASE

  6/21/2018
  17:15 – 17:30

Xiuyan Wang

Memorial Sloan Kettering Cancer Center, United States

Dr. Wang is the Assistant Director of the Cell Therapy and Cell Engineering Facility at Memorial Sloan Kettering Cancer Center. She has overseen the successful manufacturing of over 300 clinical cell products including lymphocytes and stem cells for phase I/II clinical trials, as well as viral vectors. Dr. Wang is actively participating in the National Institute for Innovation in Manufacturing Biopharmaceuticals. She is also a member for the Translational Science and Product Development Committee for ASGCT.

Presentation(s):

• 2 - CAR T CELL THERAPY: THE CD19 PARADIGM AND BEYOND

  6/21/2018
  16:05 – 16:30

Charles E. Murry

University of Washington, WA, United States

Dr. Charles (Chuck) Murry received his MD-PhD at Duke University, studying myocardial ischemia-reperfusion injury. He did residency training in Pathology at the University of Washington, followed by fellowships in vascular biology and diagnostic cardiovascular pathology. He is currently a professor of Pathology, Bioengineering, and Medicine/Cardiology at the UW. Dr. Murry’s research focuses on stem cell biology, emphasizing differentiation of the human cardiovascular system and using these cells to study diseases and to regenerate damaged tissues. His group is a world leader in heart regeneration and is working toward a clinical trial using cardiomyocyte therapy. Murry is Director of the UW Institute for Stem Cell and Regenerative Medicine, Director of the UW Medicine Heart Regeneration Program, and Co-Director of the UW Center for Cardiovascular Biology.

Presentation(s):

• 1 - TOPIC OVERVIEW BY CHAIR

  6/21/2018
  13:15 – 13:20

• 3 - HUMAN ESC-CARDIOMYOCYTES RESTORE FUNCTION IN INFARCTED NON-HUMAN PRIMATE HEARTS

  6/21/2018
  16:30 – 16:45

• ASSESSING GENOMIC INTEGRITY FOR STEM CELL CLINICAL TRIALS

  6/28/2019
  17:32 – 17:52

John M. Hallett

University of Edinburgh, United Kingdom

Presentation(s):

• 4 - THE ADULT HUMAN EPCAM+CD24+CD133+ CHOLANGIOCYTE AS A BIPOTENTIAL HUMAN HEPATIC PROGENITOR AND TRANSPLANTABLE REGENERATIVE THERAPY FOR BILIARY DISEASE.

  6/21/2018
  16:45 – 17:00

Isabelle R. de Luzy

Florey Institute of Neuroscience and Mental Health, VIC, Australia

Presentation(s):

• 5 - ISOLATION AND TRANSPLANTATION OF HUMAN PLURIPOTENT STEM CELL-DERIVED MIDBRAIN DOPAMINERGIC PROGENITORS INTO PARKINSONIAN RATS

  6/21/2018
  17:00 – 17:15

• 7 - GDNF ENHANCES THE FUNCTIONAL INTEGRATION OF HUMAN PLURIPOTENT STEM CELL-DERIVED DOPAMINE GRAFTS IN A RAT MODEL OF PARKINSON'S DISEASE

  6/22/2018
  14:45 – 15:10

Roger Barker

University of Cambridge

Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke's Hospital Cambridge. He is a guest professor at the University of Lund, Sweden and a PI in the MRC-Wellcome Trust Stem Cell Institute in Cambridge. For the last 25 years he has run research that seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson's (PD) and Huntington's disease (HD). This has helped him define the best way by which to take new treatments into the clinic, in particular cell based therapies. He currently co-ordinates an EU funded transplant programme using human fetal tissue for patients with PD and is part of a new EU and global initiative (GFORCE-PD) that is seeking to take stem cells to trial in patients with PD.

Presentation(s):

• (Stem) Cell based therapis for Parkinson's disease- Where are we?

  6/19/2018
  15:10 – 15:40

• Overview of the ISSCR's Clinical Translation Committee's work

  6/20/2018
  11:05 – 11:25

• 1 - TOPIC OVERVIEW BY CHAIR

  6/21/2018
  16:00 – 16:05

• 6 - LESSONS LEARNED FROM A CELL-BASED TRIAL IN PARKINSON’S DISEASE

  6/21/2018
  17:15 – 17:30

Silviu Itescu

Mesoblast LTD, Australia

Mesoblast founder Dr Silviu Itescu has established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He’s been a faculty member of Columbia University in New York and the University of Melbourne and Monash University in Australia. In 2013, he received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in cell-based translational science and clinical medicine.

Presentation(s):

• 7 - ROAD TO THE CLINIC THE COMMERCIALIZATION OF MESENCHYMAL LINEAGE CELLS

  6/21/2018
  17:30 – 17:55